Personal tools

DOID:162

From FANTOM5_SSTAR

Revision as of 10:33, 12 September 2014 by Autoedit (talk | contribs)
Jump to: navigation, search

Name:cancer
Namespace:disease_ontology
Definition:"A disease of cellular proliferation that is malignant and primary, characterized by uncontrolled cellular proliferation, local cell invasion and metastasis." [stedman:rlc, url:http://en.wikipedia.org/wiki/cancer, url:http://www2.merriam-webster.com/cgi-bin/mwmednlm?book
Xrefs:
links:

ICD9CM:239.4
SNOMEDCT_2010_1_31:189535002

UMLS_CUI:C0027639
Synonyms: "malignant neoplasm" EXACT []
"malignant tumor " EXACT []
"primary cancer" EXACT []

Ontology association<br>Each term has an is_a parent in the Disease Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to DISEASE ontologies.<br><br>link to ontology dataset<br>data

Parents

is_a:DOID:14566(disease of cellular proliferation)



Children


is a:DOID:0050686 (organ system cancer),DOID:0050687 (cell type cancer)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples

Human (Homo sapiens)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results Mouse (Mus musculus)

  • 10399-106A3 (acute myeloid leukemia (FAB M5) cell line:THP-1 (fresh))
  • 10400-106A4 (acute myeloid leukemia (FAB M5) cell line:THP-1 (revived))
  • 10405-106A9 (acute myeloid leukemia (FAB M5) cell line:THP-1 (thawed))
  • 10408-106B3 (lung adenocarcinoma cell line:PC-14)
  • 10409-106B4 (chronic myelogenous leukemia cell line:KU812)
  • 10410-106B5 (extraskeletal myxoid chondrosarcoma cell line:H-EMC-SS)
  • 10411-106B6 (renal cell carcinoma cell line:OS-RC-2)
  • 10412-106B7 (malignant trichilemmal cyst cell line:DJM-1)
  • 10413-106B8 (glioma cell line:GI-1)
  • 10414-106B9 (maxillary sinus tumor cell line:HSQ-89)

... further results

Enrichment analysis: top 100 FFCP enriched with this ontology termTOP 100 FANTOM5 Cage Peaks enriched with DOID:162 (cancer), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

P-valueFFCPShort description
9.96e-79FFCP PHASE2:Hg19::chrX:153991088..153991168,+#_d8b0c3734cef3039c71d0551d9b5e18ap1@DKC1
9.96e-79FFCP PHASE1:Hg19::chrX:153991088..153991168,+#_d8b0c3734cef3039c71d0551d9b5e18ap1@DKC1
3.44e-74FFCP PHASE2:Hg19::chr11:1372935..1372952,+#_fd802cbbc82d54ab0bf78af791833584p@chr11:1372935..1372952, +
3.44e-74FFCP PHASE1:Hg19::chr11:1372935..1372952,+#_fd802cbbc82d54ab0bf78af791833584p@chr11:1372935..1372952, +
3.08e-67FFCP PHASE2:Hg19::chr2:197504410..197504471,+#_e9298da4595f179c91c66c17da6e7dfap1@CCDC150
3.08e-67FFCP PHASE1:Hg19::chr2:197504410..197504471,+#_e9298da4595f179c91c66c17da6e7dfap1@CCDC150
1.07e-65FFCP PHASE1:Hg19::chr17:38444115..38444194,+#_bab7d919aabe45a070d1cf235b5fbf5dp1@CDC6
1.07e-65FFCP PHASE2:Hg19::chr17:38444115..38444194,+#_bab7d919aabe45a070d1cf235b5fbf5dp1@CDC6
2.66e-65FFCP PHASE1:Hg19::chr17:41277372..41277418,-#_cbce78e758ac3c3d8ea488d5193def09p1@BRCA1
2.66e-65FFCP PHASE2:Hg19::chr17:41277372..41277418,-#_cbce78e758ac3c3d8ea488d5193def09p1@BRCA1
7.18e-65FFCP PHASE1:Hg19::chr3:179280702..179280769,+#_1a497aec0d33d0b0f0a19e36cba51db8p1@ACTL6A
7.18e-65FFCP PHASE2:Hg19::chr3:179280702..179280769,+#_1a497aec0d33d0b0f0a19e36cba51db8p1@ACTL6A
2.18e-64FFCP PHASE1:Hg19::chr1:214776516..214776565,+#_b23a7c4cde54316bdb0f4ff3873a48f2p1@CENPF
2.18e-64FFCP PHASE2:Hg19::chr1:214776516..214776565,+#_b23a7c4cde54316bdb0f4ff3873a48f2p1@CENPF
2.34e-64FFCP PHASE1:Hg19::chr20:57617831..57617909,-#_2f8d7f2ac11d92089f8cf64ea32ea01ep1@SLMO2
2.34e-64FFCP PHASE2:Hg19::chr20:57617831..57617909,-#_2f8d7f2ac11d92089f8cf64ea32ea01ep1@SLMO2
2.6e-64FFCP PHASE2:Hg19::chr8:124408630..124408647,-#_5fda194305cf9524b8765479dac01648p2@ATAD2
2.6e-64FFCP PHASE1:Hg19::chr8:124408630..124408647,-#_5fda194305cf9524b8765479dac01648p2@ATAD2
4.32e-64FFCP PHASE2:Hg19::chrX:153991175..153991226,+#_5d00841d22f38297704bc07fc3c0c6cfp2@DKC1
4.32e-64FFCP PHASE1:Hg19::chrX:153991175..153991226,+#_5d00841d22f38297704bc07fc3c0c6cfp2@DKC1
7.63e-64FFCP PHASE2:Hg19::chr7:105162652..105162709,-#_f1db6a0286e916743ee2a21ed04a8139p1@PUS7
7.63e-64FFCP PHASE1:Hg19::chr7:105162652..105162709,-#_f1db6a0286e916743ee2a21ed04a8139p1@PUS7
1.13e-63FFCP PHASE2:Hg19::chr1:154947126..154947147,+#_a15a8b5c70555bb6cab45bd2ddc8fb17p2@CKS1B
1.13e-63FFCP PHASE1:Hg19::chr1:154947126..154947147,+#_a15a8b5c70555bb6cab45bd2ddc8fb17p2@CKS1B
2.95e-63FFCP PHASE2:Hg19::chr1:154947148..154947175,+#_14ac35d2bfee7cf4d392799cb8c84045p1@CKS1B
2.95e-63FFCP PHASE1:Hg19::chr1:154947148..154947175,+#_14ac35d2bfee7cf4d392799cb8c84045p1@CKS1B
3.81e-63FFCP PHASE2:Hg19::chr8:124408652..124408712,-#_c13c877baac7f299173faf1dff1e9b20p1@ATAD2
3.81e-63FFCP PHASE1:Hg19::chr8:124408652..124408712,-#_c13c877baac7f299173faf1dff1e9b20p1@ATAD2
1.66e-62FFCP PHASE1:Hg19::chr1:214776570..214776593,+#_1093b2b699893358a8b0516c6b403362p2@CENPF
1.66e-62FFCP PHASE2:Hg19::chr1:214776570..214776593,+#_1093b2b699893358a8b0516c6b403362p2@CENPF
2.3e-62FFCP PHASE2:Hg19::chr4:57301645..57301675,-#_bfa11d4a54514d6f221f7bce9fad8712p2@PPAT
2.3e-62FFCP PHASE1:Hg19::chr4:57301645..57301675,-#_bfa11d4a54514d6f221f7bce9fad8712p2@PPAT
2.38e-62FFCP PHASE2:Hg19::chr1:211848955..211848981,-#_eba171b59f0a24c932a449db92fbfbb8p1@NEK2
2.38e-62FFCP PHASE1:Hg19::chr1:211848955..211848981,-#_eba171b59f0a24c932a449db92fbfbb8p1@NEK2
5.44e-62FFCP PHASE1:Hg19::chr17:38574169..38574180,-#_b43fc8c57b6e5112fdc9cc5993e9de98p2@TOP2A
5.44e-62FFCP PHASE2:Hg19::chr17:38574169..38574180,-#_b43fc8c57b6e5112fdc9cc5993e9de98p2@TOP2A
6.99e-62FFCP PHASE2:Hg19::chr5:34915805..34915847,+#_2bea4c8579e8ee77eeb206ed3ba1350cp1@BRIX1
6.99e-62FFCP PHASE1:Hg19::chr5:34915805..34915847,+#_2bea4c8579e8ee77eeb206ed3ba1350cp1@BRIX1
8.22e-62FFCP PHASE1:Hg19::chr3:172468505..172468582,+#_0aa2b79ecc1294441bf0699168559251p1@ECT2
8.22e-62FFCP PHASE2:Hg19::chr3:172468505..172468582,+#_0aa2b79ecc1294441bf0699168559251p1@ECT2
8.85e-62FFCP PHASE2:Hg19::chr2:198364552..198364576,-#_c29cfad6f7ecaf1fd9bdc8c56f05401bp1@HSPD1
8.85e-62FFCP PHASE1:Hg19::chr2:198364552..198364576,-#_c29cfad6f7ecaf1fd9bdc8c56f05401bp1@HSPD1
9.36e-62FFCP PHASE2:Hg19::chr12:4647995..4648087,+#_e82e53e664a9e6aca2b896a7cffc4f74p1@RAD51AP1
9.36e-62FFCP PHASE1:Hg19::chr12:4647995..4648087,+#_e82e53e664a9e6aca2b896a7cffc4f74p1@RAD51AP1
9.57e-62FFCP PHASE2:Hg19::chr11:125495862..125495882,+#_9dd1f94d374b079eaa9e41918d62bdc6p1@CHEK1
9.57e-62FFCP PHASE1:Hg19::chr11:125495862..125495882,+#_9dd1f94d374b079eaa9e41918d62bdc6p1@CHEK1
1.63e-61FFCP PHASE2:Hg19::chr12:118454500..118454585,+#_ec3bb1ab3e2c7b77f070a9a752cc84aap1@RFC5
1.63e-61FFCP PHASE1:Hg19::chr12:118454500..118454585,+#_ec3bb1ab3e2c7b77f070a9a752cc84aap1@RFC5
1.64e-61FFCP PHASE2:Hg19::chr17:38574125..38574168,-#_4676515ba606590fa409795b095ee3f1p1@TOP2A
1.64e-61FFCP PHASE1:Hg19::chr17:38574125..38574168,-#_4676515ba606590fa409795b095ee3f1p1@TOP2A
2.18e-61FFCP PHASE2:Hg19::chr7:56119449..56119492,+#_1234d05a38a605e77fd0013dd0828226p1@CCT6A
2.18e-61FFCP PHASE1:Hg19::chr7:56119449..56119492,+#_1234d05a38a605e77fd0013dd0828226p1@CCT6A
7.19e-61FFCP PHASE2:Hg19::chr5:37288836..37288849,-#_9ca35e41650acdb579efd3be2bddd47bp@chr5:37288836..37288849, -
7.19e-61FFCP PHASE1:Hg19::chr5:37288836..37288849,-#_9ca35e41650acdb579efd3be2bddd47bp@chr5:37288836..37288849, -
7.2e-61FFCP PHASE2:Hg19::chr1:242011485..242011542,+#_0064c5c08ea96464bcf816c2e12270dcp1@EXO1
7.2e-61FFCP PHASE1:Hg19::chr1:242011485..242011542,+#_0064c5c08ea96464bcf816c2e12270dcp1@EXO1
9.06e-61FFCP PHASE2:Hg19::chr10:96363899..96363904,+#_8f61d266262a5bcac520455551e38ebap@chr10:96363899..96363904, +
9.06e-61FFCP PHASE1:Hg19::chr10:96363899..96363904,+#_8f61d266262a5bcac520455551e38ebap@chr10:96363899..96363904, +
1.15e-60FFCP PHASE1:Hg19::chr2:29117521..29117569,+#_cf6b6bf6d2688af83e9d2dc7cde44f11p1@WDR43
1.15e-60FFCP PHASE2:Hg19::chr2:29117521..29117569,+#_cf6b6bf6d2688af83e9d2dc7cde44f11p1@WDR43
3.12e-60FFCP PHASE1:Hg19::chr2:70529150..70529179,-#_2348b90e0f4a82abc44b2055b92d07d2p1@FAM136A
3.12e-60FFCP PHASE2:Hg19::chr2:70529150..70529179,-#_2348b90e0f4a82abc44b2055b92d07d2p1@FAM136A
5.18e-60FFCP PHASE2:Hg19::chr8:130951991..130952083,-#_c0069b8820d5ee577d979c5b680d6b34p1@FAM49B
5.18e-60FFCP PHASE1:Hg19::chr8:130951991..130952083,-#_c0069b8820d5ee577d979c5b680d6b34p1@FAM49B
6.2e-60FFCP PHASE2:Hg19::chr5:37371163..37371231,-#_bb10e28ecc2f48ab5085148de102b8bfp1@NUP155
6.2e-60FFCP PHASE1:Hg19::chr5:37371163..37371231,-#_bb10e28ecc2f48ab5085148de102b8bfp1@NUP155
7.13e-60FFCP PHASE1:Hg19::chr18:19192235..19192337,+#_dae9cbc994193a6ff8644275dd8f6738p1@SNRPD1
7.13e-60FFCP PHASE2:Hg19::chr18:19192235..19192337,+#_dae9cbc994193a6ff8644275dd8f6738p1@SNRPD1
1.32e-59FFCP PHASE1:Hg19::chr1:68962744..68962772,-#_6ec1996ff7754008226a84bb47b8b366p1@DEPDC1
1.32e-59FFCP PHASE2:Hg19::chr1:68962744..68962772,-#_6ec1996ff7754008226a84bb47b8b366p1@DEPDC1
1.54e-59FFCP PHASE2:Hg19::chr15:40453204..40453304,+#_9fd37529bdb1fa16f012c03396fa4321p1@BUB1B
1.54e-59FFCP PHASE1:Hg19::chr15:40453204..40453304,+#_9fd37529bdb1fa16f012c03396fa4321p1@BUB1B
1.97e-59FFCP PHASE2:Hg19::chr15:41625060..41625088,+#_28c02d1a08d19c6820a441d5ad4439f2p1@NUSAP1
1.97e-59FFCP PHASE1:Hg19::chr15:41625060..41625088,+#_28c02d1a08d19c6820a441d5ad4439f2p1@NUSAP1
4.08e-59FFCP PHASE2:Hg19::chr12:57146095..57146149,-#_e0f4d3e6943a38bde428db1b8b02f915p1@PRIM1
4.08e-59FFCP PHASE1:Hg19::chr12:57146095..57146149,-#_e0f4d3e6943a38bde428db1b8b02f915p1@PRIM1
4.93e-59FFCP PHASE1:Hg19::chr15:91537809..91537824,-#_b22b28d8c476f7bce74c81601317e2a1p2@PRC1
4.93e-59FFCP PHASE2:Hg19::chr15:91537809..91537824,-#_b22b28d8c476f7bce74c81601317e2a1p2@PRC1
5.19e-59FFCP PHASE2:Hg19::chr15:89787185..89787263,+#_77c7995359dd9eb90391b080cc4e838bp1@FANCI
5.19e-59FFCP PHASE1:Hg19::chr15:89787185..89787263,+#_77c7995359dd9eb90391b080cc4e838bp1@FANCI
5.72e-59FFCP PHASE2:Hg19::chr7:152373216..152373260,-#_d4341dda3ea184ea62d141fe9c1bd306p1@XRCC2
5.72e-59FFCP PHASE1:Hg19::chr7:152373216..152373260,-#_d4341dda3ea184ea62d141fe9c1bd306p1@XRCC2
6.59e-59FFCP PHASE2:Hg19::chr4:154265825..154265875,+#_956b476bdb576b8b46ba0e905d63cb06p1@MND1
6.59e-59FFCP PHASE1:Hg19::chr4:154265825..154265875,+#_956b476bdb576b8b46ba0e905d63cb06p1@MND1
7.67e-59FFCP PHASE1:Hg19::chr17:48450575..48450618,+#_d2249659e41ae7160acacd35d933fff0p1@EME1
7.67e-59FFCP PHASE2:Hg19::chr17:48450575..48450618,+#_d2249659e41ae7160acacd35d933fff0p1@EME1
1.11e-58FFCP PHASE2:Hg19::chr15:69706740..69706754,+#_47359bd07ca880b84506d9d2fd3d39edp2@KIF23
1.11e-58FFCP PHASE1:Hg19::chr15:69706740..69706754,+#_47359bd07ca880b84506d9d2fd3d39edp2@KIF23
2.3e-58FFCP PHASE2:Hg19::chr6:20402102..20402152,+#_7bf6948701bd615c0268be70b9e253a6p1@E2F3
2.3e-58FFCP PHASE1:Hg19::chr6:20402102..20402152,+#_7bf6948701bd615c0268be70b9e253a6p1@E2F3
4.85e-58FFCP PHASE1:Hg19::chr10:62538228..62538244,+#_97190b1e8fdcc55f8a1018aca2af1780p1@CDK1
4.85e-58FFCP PHASE2:Hg19::chr10:62538228..62538244,+#_97190b1e8fdcc55f8a1018aca2af1780p1@CDK1
5.95e-58FFCP PHASE2:Hg19::chr2:113522177..113522228,-#_46abf9e813609327fe05eed4f71fd17bp1@CKAP2L
5.95e-58FFCP PHASE1:Hg19::chr2:113522177..113522228,-#_46abf9e813609327fe05eed4f71fd17bp1@CKAP2L
7.72e-58FFCP PHASE1:Hg19::chr17:57233087..57233146,+#_ae213e1e27bfbbc6ef55b9bedf09e998p1@PRR11
7.72e-58FFCP PHASE2:Hg19::chr17:57233087..57233146,+#_ae213e1e27bfbbc6ef55b9bedf09e998p1@PRR11
9.18e-58FFCP PHASE2:Hg19::chr17:38552615..38552637,-#_29b6fdb9d877203762ac6ea3bd20c130p@chr17:38552615..38552637, -
9.18e-58FFCP PHASE1:Hg19::chr17:38552615..38552637,-#_29b6fdb9d877203762ac6ea3bd20c130p@chr17:38552615..38552637, -
9.86e-58FFCP PHASE2:Hg19::chr3:186524234..186524303,-#_e2294347da69e94f736bbd5a84cebe4ap1@RFC4
9.86e-58FFCP PHASE1:Hg19::chr3:186524234..186524303,-#_e2294347da69e94f736bbd5a84cebe4ap1@RFC4

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=DOID:162&oldid=3272298"